222 related articles for article (PubMed ID: 19349520)
1. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
Govorkova EA; Ilyushina NA; McClaren JL; Naipospos TS; Douangngeun B; Webster RG
Antimicrob Agents Chemother; 2009 Jul; 53(7):3088-96. PubMed ID: 19349520
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Takano R; Kiso M; Igarashi M; Le QM; Sekijima M; Ito K; Takada A; Kawaoka Y
J Infect Dis; 2013 Jan; 207(1):89-97. PubMed ID: 23053629
[TBL] [Abstract][Full Text] [Related]
3. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
[TBL] [Abstract][Full Text] [Related]
5. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
6. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
J Virol; 2010 Aug; 84(16):8042-50. PubMed ID: 20519385
[TBL] [Abstract][Full Text] [Related]
7. Neuraminidase inhibitors susceptibility profiles of highly pathogenic influenza A (H5N1) viruses isolated from avian species in India (2006-2015).
Sood R; Kumar N; Bhatia S; Chanu KV; Gupta CL; Pateriya AK; Mishra A; Khandia R; Mawale N; Singh VP
Antiviral Res; 2018 Oct; 158():143-146. PubMed ID: 30125616
[TBL] [Abstract][Full Text] [Related]
8. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
11. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
[TBL] [Abstract][Full Text] [Related]
12. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Kiso M; Ozawa M; Le MT; Imai H; Takahashi K; Kakugawa S; Noda T; Horimoto T; Kawaoka Y
J Virol; 2011 May; 85(10):4667-72. PubMed ID: 21367898
[TBL] [Abstract][Full Text] [Related]
13. Assessing the susceptibility of highly pathogenic avian influenza H5N1 viruses to oseltamivir using embryonated chicken eggs.
Tare DS; Kode SS; Hurt AC; Pawar SD
Indian J Med Res; 2019 Nov; 150(5):486-491. PubMed ID: 31939392
[TBL] [Abstract][Full Text] [Related]
14. Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.
Govorkova EA; Baranovich T; Seiler P; Armstrong J; Burnham A; Guan Y; Peiris M; Webby RJ; Webster RG
Antiviral Res; 2013 May; 98(2):297-304. PubMed ID: 23458714
[TBL] [Abstract][Full Text] [Related]
15. I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A(H5N1) viruses.
McKimm-Breschkin JL; Barrett S; Pudjiatmoko ; Azhar M; Wong FY; Selleck P; Mohr PG; McGrane J; Kim M
PLoS One; 2013; 8(6):e66105. PubMed ID: 23776615
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
Govorkova EA; Ilyushina NA; Boltz DA; Douglas A; Yilmaz N; Webster RG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1414-24. PubMed ID: 17296744
[TBL] [Abstract][Full Text] [Related]
17. Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
Cardoso FM; Ibañez LI; Van den Hoecke S; De Baets S; Smet A; Roose K; Schepens B; Descamps FJ; Fiers W; Muyldermans S; Depicker A; Saelens X
J Virol; 2014 Aug; 88(15):8278-96. PubMed ID: 24829341
[TBL] [Abstract][Full Text] [Related]
18. Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility.
McKimm-Breschkin JL; Barrett S; Wong FYK; Pudjiatmoko ; Azhar M; Selleck P; Davies KR; Hartaningsih N; McGrane J
Antiviral Res; 2018 May; 153():95-100. PubMed ID: 29574145
[TBL] [Abstract][Full Text] [Related]
19. A novel I117T substitution in neuraminidase of highly pathogenic avian influenza H5N1 virus conferring reduced susceptibility to oseltamivir and zanamivir.
Kode SS; Pawar SD; Tare DS; Keng SS; Hurt AC; Mullick J
Vet Microbiol; 2019 Aug; 235():21-24. PubMed ID: 31282375
[TBL] [Abstract][Full Text] [Related]
20. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
